Hey, today's journal is gonna be different, I am gonna do a daily stock pick, and a small market pick from the NASDAQ.
**********************************
Today's pick is Maxim Pharmaceuticals (NASDAQ symbol MAXM). They are a global biopharmaceutical company with a diverse pipeline of drug candidates for life-threatening cancers, hepatitis C and other chronic liver diseases. The Company's lead drug candidate, Ceplene (histamine dihydrochloride), is designed to prevent or reverse damage associated with oxidative stress, thereby protecting immune cells and other critical cells and tissue. Because Ceplene impacts basic immune functions, it has the potential to be used in a broad range of diseases in which oxidative stress plays an important role. More than 1,600 patients have participated in Maxim's 17 completed and ongoing clinical trials of Ceplene in diseases, including life-threatening cancers, such as advanced metastatic melanoma (a deadly form of skin cancer), acute myelogenous leukemia and renal cell carcinoma (kidney cancer) and hepatitis C (a blood-borne virus).
For the nine months ended 6/30/03, revenues rose 29% to $2.3M. Net loss before accounting change increased 31% to $32.7 million. Results reflect higher research revenues, offset by increased research and development expense.
On a scale of 1.0 (Strong Buy) to 5.0 (Strong Sell) I rate this stock at a 2.0. It's current trading price is US 7.35 a share.
**********************************
Today's small market NASDAQ pick is ebix.com (NASDAQ symbol EBIX). ebix.com, Inc. markets software to insurance agents and brokers operating in the insurance industry, and provides customer support and maintenance services, as well as other implementation and consulting services such as training, data conversion, installation software development and call center. The Company focuses on the worldwide sales and support of agency management systems led by ebixASP; expansion of connectivity between consumers, agents, carriers and third-party providers through ebix.com, INS-Site and ebixExchange, and business process services that include software development, call center and back office, either off site or at its facilities.
I have no information available on their financial profile, other than their profits were up from the previous quarter, and their stock rose 20+% on Friday. They are currently trading at 10.16 a share.
**********************************
My final tip for the day is this: Start out small, work your way up, and for cryin out loud, read the Wall Street Journal! Peace, I am out.
**********************************
Today's pick is Maxim Pharmaceuticals (NASDAQ symbol MAXM). They are a global biopharmaceutical company with a diverse pipeline of drug candidates for life-threatening cancers, hepatitis C and other chronic liver diseases. The Company's lead drug candidate, Ceplene (histamine dihydrochloride), is designed to prevent or reverse damage associated with oxidative stress, thereby protecting immune cells and other critical cells and tissue. Because Ceplene impacts basic immune functions, it has the potential to be used in a broad range of diseases in which oxidative stress plays an important role. More than 1,600 patients have participated in Maxim's 17 completed and ongoing clinical trials of Ceplene in diseases, including life-threatening cancers, such as advanced metastatic melanoma (a deadly form of skin cancer), acute myelogenous leukemia and renal cell carcinoma (kidney cancer) and hepatitis C (a blood-borne virus).
For the nine months ended 6/30/03, revenues rose 29% to $2.3M. Net loss before accounting change increased 31% to $32.7 million. Results reflect higher research revenues, offset by increased research and development expense.
On a scale of 1.0 (Strong Buy) to 5.0 (Strong Sell) I rate this stock at a 2.0. It's current trading price is US 7.35 a share.
**********************************
Today's small market NASDAQ pick is ebix.com (NASDAQ symbol EBIX). ebix.com, Inc. markets software to insurance agents and brokers operating in the insurance industry, and provides customer support and maintenance services, as well as other implementation and consulting services such as training, data conversion, installation software development and call center. The Company focuses on the worldwide sales and support of agency management systems led by ebixASP; expansion of connectivity between consumers, agents, carriers and third-party providers through ebix.com, INS-Site and ebixExchange, and business process services that include software development, call center and back office, either off site or at its facilities.
I have no information available on their financial profile, other than their profits were up from the previous quarter, and their stock rose 20+% on Friday. They are currently trading at 10.16 a share.
**********************************
My final tip for the day is this: Start out small, work your way up, and for cryin out loud, read the Wall Street Journal! Peace, I am out.
london:
9 and a half days?